STOCK TITAN

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on Dec. 5-6, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

MELVILLE, N.Y., Nov. 29, 2022 - BioRestorative Therapies, Inc. (BRTX) announces CEO Lance Alstodt's participation in the RHK Capital Disruptive Growth Conference in New York City on December 5-6, 2022. This event will gather executives from 30 disruptive companies and institutional investors, market analysts, and financial advisors. BioRestorative focuses on therapeutic products utilizing adult stem cells for treating spinal and metabolic disorders, featured in their core programs brtxDISC™ and ThermoStem®.

Positive
  • None.
Negative
  • None.

MELVILLE N.Y., Nov. 29, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BioRestorative Therapies, Inc. (Nasdaq: BRTX) today announced that Lance Alstodt, its CEO, will be participating at the RHK Capital Disruptive Growth Conference in New York City.

EventRHK Capital Disruptive Growth Conference
DatesDecember 5-6, 2022
LocationNew York City

The RHK Capital Disruptive Growth Conference will feature leading C-suite executives and senior management of up to 30 growth-oriented and disruptive companies to meet with seasoned institutional investors, accredited investors, representatives of family offices, market analysts and financial advisors, as well as broker-dealer wealth managers and select RHK clients.

To learn more and submit a registration request, visit http://disruptnyc.com/

ABOUT BioRestorative Therapies

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

• Disc/Spine Program (brtxDISC ™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. Pursuant to authorization received from the Food and Drug Administration, we have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.

• Metabolic Program (ThermoStem ®): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Contact:
Email: ir@biorestorative.com
Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

 


FAQ

What event will BioRestorative Therapies participate in?

BioRestorative Therapies will participate in the RHK Capital Disruptive Growth Conference.

When is the RHK Capital Disruptive Growth Conference?

The conference is scheduled for December 5-6, 2022.

Where is the RHK Capital Disruptive Growth Conference held?

The conference will take place in New York City.

Who is representing BioRestorative Therapies at the conference?

CEO Lance Alstodt will represent BioRestorative Therapies at the conference.

What is the focus of BioRestorative Therapies?

BioRestorative Therapies focuses on therapeutic products using adult stem cell protocols.

BioRestorative Therapies, Inc.

NASDAQ:BRTX

BRTX Rankings

BRTX Latest News

BRTX Stock Data

10.45M
5.08M
26.61%
13.74%
1.08%
Biotechnology
Services-misc Health & Allied Services, Nec
Link
United States of America
MELVILLE